U.S. markets closed

AXIM Biotechnologies, Inc. (AXIM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6698-0.0012 (-0.18%)
At close: 3:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6710
Open0.6790
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6500 - 0.6845
52 Week Range0.3940 - 1.2200
Volume36,869
Avg. Volume138,688
Market Cap89.259M
Beta (5Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0770
Earnings DateMay 01, 2018 - May 07, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AXIM BIOTECHNOLOGIES INC
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
    Rating
    Fair Value
    Economic Moat
    26 days agoMorningstar
View more